Design and created by Guideline Central in participation with the Cystic Fibrosis Foundation.
Cystic Fibrosis Foundation
Publication Date: Aug 1, 2014
Page Last Updated: May 5, 2026
| Rank | Description |
| Category IA | A strong recommendation supported by high to moderate quality evidence suggesting net clinical benefits or harms. |
| Category IB | A strong recommendation supported by low-quality evidence suggesting net clinical benefits or harms, or an accepted practice (e.g., aseptic technique) supported by low to very low-quality evidence. |
| Category IC | A strong recommendation required by state or federal regulation. |
| Category II | A weak recommendation supported by any quality evidence suggesting a tradeoff between clinical benefits and harms. |
| NR = No Recommendation | Suggested for implementation and supported by suggestive clinical or epidemiologic studies or a theoretical rationale |
| U = Unresolved Issue | Practices for which insufficient evidence or no consensus regarding efficacy exist |
| Low = Certainty: Low | <80% agreed with statement by anonymous voting and thus insufficient evidence exists to recommend for or against |
D003550 - Cystic Fibrosis
D003550 - Cystic Fibrosis
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.